Pharma / Mature Biotech

We group profitable drug manufacturers and mature biotech companies separately from pre-revenue biotech because their economics are already commercial. The money-flow engine follows product revenue, gross profit, R&D expense, SG&A, operating cash flow, capital expenditure, and free cash flow, with explicit attention to how research spend coexists with positive owner earnings.

Unlike early-stage biotech, these businesses can still be assessed with longer-duration valuation assumptions. The StatsAlpha(TM) fair-value defaults keep the category in the broader biotech-pharma DCF family, using elevated discount rates and slower terminal assumptions than software while acknowledging that binary pipeline risk still matters. The codebase even notes that a probability-of-success layer would improve the valuation story when pipeline outcomes dominate.

For durability, the framework uses the general corporate moat template because the relevant questions are still classic competitive ones: pricing power, customer stickiness, capital efficiency, resilience, and scale. The difference is that R&D and patent renewal sit much closer to the center of the interpretation. This framework is for informational purposes only, not investment advice.